Dr. Reddy’s infuses Rs. 565 crore in its Russian subsidiary
The company has made an investment of Rs. 565.40 crore in DRL Russia for a total equity stake of 45.19%
The company has made an investment of Rs. 565.40 crore in DRL Russia for a total equity stake of 45.19%
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats
She was Group Chief Marketing Officer at CKA Birla Group in her last role
Upgrades 2025 full-year CDMO sales and margin outlook
Shelcal Total marks the brand’s evolution into a modern, consumer-focused nutrition portfolio
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.
Subscribe To Our Newsletter & Stay Updated